Skip to main content
Clinical Trials/2024-515074-26-00
2024-515074-26-00
Not yet recruiting
Phase 1

A study to evaluate the safety and tolerability of single ascending doses of AGMB-101 in healthy participants (Part A) and patients with liver cirrhosis (Part B).

AgomAb Therapeutics1 site in 1 country64 target enrollmentFebruary 21, 2025

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
AgomAb Therapeutics
Enrollment
64
Locations
1
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
euclinicaltrials.eu
Start Date
February 21, 2025
End Date
TBD
Last Updated
last year

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Clinical Operations

Scientific

AgomAb Therapeutics

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Study Sites (1)

Loading locations...

Similar Trials